JMIR Research Protocols (Nov 2020)

Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial

  • Dabira, Edgard Diniba,
  • Soumare, Harouna M,
  • Lindsay, Steven W,
  • Conteh, Bakary,
  • Ceesay, Fatima,
  • Bradley, John,
  • Kositz, Christian,
  • Broekhuizen, Henk,
  • Kandeh, Balla,
  • Fehr, Alexandra E,
  • Nieto-Sanchez, Claudia,
  • Ribera, Joan Muela,
  • Peeters Grietens, Koen,
  • Smit, Menno Roderick,
  • Drakeley, Chris,
  • Bousema, Teun,
  • Achan, Jane,
  • D’Alessandro, Umberto

DOI
https://doi.org/10.2196/20904
Journal volume & issue
Vol. 9, no. 11
p. e20904

Abstract

Read online

BackgroundWith a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission. ObjectiveThe study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions. MethodsThe study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans. ResultsThe MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked. ConclusionsThis is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission. Trial RegistrationClinicalTrials.gov NCT03576313; https://clinicaltrials.gov/ct2/show/NCT03576313 International Registered Report Identifier (IRRID)DERR1-10.2196/20904